All In Biotech

Drug Trial Radar · NCT02193074

A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy

A Phase 3, Randomized, Double-Blind, Sham-Procedure Controlled Study to Assess the Clinical Efficacy and Safety of ISIS 396443 Administered Intrathecally in Patients With Infantile-onset Spinal Muscular Atrophy

Last checked: Nov 20, 2026Latest source record: Feb 17, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 122 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

122

Actual

Start

Aug 19, 2014

Primary completion

Nov 21, 2016

Study completion Nov 21, 2016

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Jul 17, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, up to 210 days
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to examine the clinical efficacy of nusinersen (ISIS 396443) administered intrathecally (IT) to participants with infantile-onset with infantile-onset spinal muscular atrophy (SMA). The secondary objective of the study is to examine the safety and tolerability of nusinersen administered intrathecally to participants with infantile-onset SMA.

Conditions

  • Spinal Muscular Atrophy

Interventions

  • nusinersenDrug

    Administered by intrathecal (IT) injection as specified in the treatment arm.

  • Sham procedureProcedure

    Small needle prick on the lower back at the location where the IT injection is normally made

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Motor Milestones RespondersTime frame: assessed at the later of the Day 183, Day 302, or Day 394 study visits
  2. Time to Death or Permanent VentilationTime frame: Day 91, Day 182, Day 273, Day 364, Day 394

Locations

31 sites in 13 countries. Site status is shown where the registry gives one.

  • UCLA Medical Center

    Los Angeles, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • Nemours Children's Hospital

    Orlando, Florida

  • Ann and Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • Boston Children's Hospital

    Boston, Massachusetts

  • Washington University School of Medicine

    St Louis, Missouri

  • Columbia University Medical Center

    New York, New York

  • Duke Children's Hospital

    Durham, North Carolina

  • Doernbecher Children's Hospital

    Portland, Oregon

  • Children's Hospital of Philadelphia - Neurology

    Philadelphia, Pennsylvania

  • UT Southwestern Medical Center/Children's Medical Center Dallas

    Dallas, Texas

  • Primary Children's Medical Center (University of Utah)

    Salt Lake City, Utah

  • Sydney Children's Hospital

    Sydney, New South Wales, Australia

  • Royal Children's Hospital, Children's Neuroscience Centre

    Parkville, Victoria, Australia

  • Hôpital Universitaire des Enfants Reine FABIOLA (HUDERF)

    Brussels, Belgium

  • British Columbia Children's Hospital/UBC

    Vancouver, British Columbia, Canada

  • Hospital for Sick Children

    Toronto, Ontario, Canada

  • Institut de Myologie

    Paris, France

  • Universitatsklinikum Essen

    Essen, Germany

  • Universtatsklinikum Freiburg, Zentrum fur Kinder-und Jugendmedizin , Abteilung Neuropadiatrie und Muskelerkrankungen

    Freiburg im Breisgau, Germany

  • Istituto Giannina Gaslini, Centro Traslazionale di Miologia e Patologie Neurodegenerative

    Genova, Italy

  • Pediatric Neurology Unit, Catholic University

    Rome, Italy

  • Tokyo Women's Medical University

    Tokyo, Japan

  • Hyogo College of Medicine

    Nishinomiya, Hyōgo, Japan

  • Seoul National University Hospital

    Seoul, South Korea

  • Hospital Universitario Vall d'Hebron

    Barcelona, Spain

  • Hospital Universitario La Paz, Pediatric Neurology Department

    Madrid, Spain

  • University of Gothenburg, The Queen Silvia Children's Hospital

    Gothenburg, Sweden

  • Hacettepe Children's Hospital

    Ankara, Turkey (Türkiye)

  • UCL Institute of Child Health/Great Ormond Street

    London, United Kingdom

  • MRC Centre for Neuromuscular Diseases at Newcastle, Institute of Genetic Medicine Newcastle University

    Newcastle, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.